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T
he diagnosis of periimplantitis
describes a pathological condi-
tion occurring in tissues around
dental implants, characterized by inflam-
mation in the periimplant connective
tissue and the progressive loss of sup-
portive bone.1 As substantial evi-
dence supports the bacterial
etiology of periimplantitis,2 the treat-
ment of the disease should include
anti-infective measures.
Based on the current evidence, non-
surgical treatments, includingmechanical
debridement with or without adjunctive
(ie, local antibiotics, antimicrobial photo-
dynamic therapy) or alternative measures
(eg, air abrasive devices, Er:YAG laser
monotherapy), have demonstrated
limited efficacy for the management of
periimplantitis andwereparticularly com-
promised at advanced defect sites.3,4
These findings may be mainly attributed
to the limit access of nonsurgical meas-
ures to advanced pockets and the inability
to completely remove bacterial deposits
from structured implant surfaces.
In contrast, surgical interventions
have been shown to improve the efficacy
of periimplantitis treatment.4 They pro-
vide better access to the periimplant
defect, which, in turn, allows for a more
effective implant surface decontamina-
tion.4Although nonaugmentative surgical
treatment approaches including open-flap
debridement (OFD) alone or with adjunc-
tive resective therapy (eg, pocket elimina-
tion, bone recontouring, and
implantoplasty) primarily aims at resolv-
ing inflammation and arresting the further
progression of the disease, augmentative
treatments additionally seek to reconstruct
the osseous defect compartment.5
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Objectives: To address the
focused question: “In patients with
osseointegrated implants diagnosed
with periimplantitis, what are the
clinical and radiographic outcomes
of augmentative surgical interven-
tions compared with nonaugmenta-
tive surgical measures”?
Material and Methods: Litera-
ture screening was performed in
MEDLINE through the PubMed
database, for articles published until
January 1, 2018. Human studies
reporting on the clinical (ie, bleeding
on probing [BOP] and probing depth
[PD] changes) and/or radiographic
(ie, periimplant defect reduction and/
or fill) treatment outcomes after sur-
gical augmentative periimplantitis
therapy, and/or comparing augmen-
tative and nonaugmentative surgical
approaches were searched.
Results: Thirteen comparative
and 11 observational clinical studies
were included. Surgical augmenta-
tive periimplantitis therapy resulted
in mean BOP and PD reduction
ranging from 26% to 91%, and 0.74
to 5.4 mm, respectively. The reported
mean radiographic fill of intrabony
defects ranged between 57% and
93.3%, and defect vertical reduction
varied from 0.2 to 3.77 mm. Three
randomized controlled clinical studies
failed to demonstrate the superiority
of augmentative therapy compared
with nonaugmentative approach in
terms of PD and BOP reduction.
Conclusions: The available evi-
dence to support superiority of aug-
mentative surgical techniques for
periimplantitis management on the
treatment outcomes over nonaugmen-
tative methods is limited. (Implant
Dent 2019;28:187–209)
Key Words: periimplant disease,
regeneration, management, aug-
mentation
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Numerous augmentation protocols
using various methods for surface
decontamination, along with autoge-
nous bone and various bone replace-
ment materials with or without barrier
membranes, have been proposed for
the management of periimplantitis.
Until now, it remains difficult to draw
conclusions concerning which aug-
mentative protocol is superior as well
as to evaluate its clinical efficacy over
nonaugmentative treatments.6,7
Therefore, the aim of the present
review is to evaluate the existing evi-
dence regarding the effectiveness of
surgical augmentative therapy for peri-
implantitis management and to compare
it with nonaugmentative therapy alone.
MATERIALS AND METHODS
The reporting of this systematic
analysis adhered to the PreferredReport-
ing Items for Systematic Review and
Meta-Analyses (PRISMA) statement.8
Focus Questions
The following questions were
developed according to the population,
intervention, comparison, and outcome
(PICO) study design:
“In patients with osseointe-
grated implants diagnosed
with periimplantitis, what are
the clinical and radiographic
outcomes of augmentative
surgical interventions com-
pared with nonaugmentative
surgical measures?”
Population: Patients diagnosed
with periimplantitis based on case def-
initions used in respective publications;
Intervention: Surgical augmenta-
tive periimplantitis measures;
Comparison: Surgical nonaugmen-
tative measures.
Outcomes: primary: changes in
clinical parameters (ie, bleeding on
probing [BOP%] and periimplant prob-
ing depth [PD {mm}]; secondary:
radiographic defect fill [%] and/or
defect reduction (mm).
Search Strategy
A literature searchwas performed in
MEDLINE through the PubMed data-
base of the US National Library of
Medicine, for articles published until
January 1, 2018. The combination of
Medical Subject Heading search terms
(ie,MeSH) and free-text terms included:
“peri-implant disease” OR
“periimplant disease” OR
“peri-implant infection” OR
“periimplant infection” OR
“peri-implantitis” OR “Peri-
implantitis (MeSH)”
AND
“treatment” OR “surgical treat-
ment” OR “regenerative treatment”
OR “augmentative treatment” OR
“augmentative therapy” OR “surgical
therapy” OR “regenerative therapy”
OR “reconstructive treatment” OR
“reconstructive therapy” OR “aug-
mentative therapy” OR “augmentative
treatment”.
Selection of Studies
Two independent reviewers (A.R.
and K.O.) conducted the literature
search. Disagreements regarding inclu-
sion during the first and second stages
of the study selection were resolved by
discussion.
During the first stage of study
selection, the titles and abstracts were
screened and evaluated according to the
following inclusion criteria:
1. Prospective, randomized, con-
trolled clinical trials (RCTs), case-
control studies, prospective cohort
studies, cross-sectional studies, and
case series in humans reporting
changes in clinical parameters
(ie, BOP and PD), and/or present-
ing radiographic data (defect
reduction [mm] and/or defect fill)
after surgical augmentative treat-
ment and/or comparing augmenta-
tive and nonaugmentative surgical
approaches with a follow-up of at
least 3 months;
2. Studies that include patientswith at
least one osseointegrated implant
affected by periimplantitis;
3. Studies describing the definition
of periimplantitis;
4. Studies presenting a surgical aug-
mentative intervention aimed at
the treatment of periimplantitis;
5. Publications in English language
in an international, peer-reviewed
journal.
At the second stage of selection, all
full-text articles identified during the
first stage were acquired and evaluated
according to the following exclusion
criteria:
Fig. 1. The flowchart presenting literature search.
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Table 1. Study and Patient Characteristics: Comparative Studies
Author Study Design Case Definition (Defect Type) Follow-up Period
No. of Patients/
Implants
1. Khoury and Buchmann
200134
Controlled clinical study Bone loss .50% of implant length +
intrabony crater-form defect
3 y 25/41
Test 1: 20 implants
Test 2: 9 implants
Control: 12 implants
2. Deppe et al,39 2007 Controlled clinical study PD $5 mm + BOP + progressive vertical
bone loss
5 y 16/32
Test: 9/17
Control: 7/15
3. Schwarz et al,23,41,42 2006,
2008, 2009
RCT PD .6 mm, BOP/pus + intrabony
component .3 mm
4 y 20/21
Test: 9/9
Control: 10/11
4. Schwarz et al,26 2010 Controlled clinical study PD .6 mm + BOP/pus + intrabony defect
component .3 mm + supracrestal
component #1 mm
12 mo 27/27
Test Ib: 9/9
Ic: 9/9
Control: 9/9
5. Aghazadeh et al,22 2012 RCT PD$5 mm + BOP/Pus + radiographic bone
loss $2 mm + angular periimplant bone
defect $3 mm
12 mo 45/71
Test: 23/37
Control: 22/34
6. Wohlfahrt et al,18 2012 RCT PD $5 mm + BOP + 1-, 2-, 3-wall intrabony
defects $4 mm depth
12 mo 32/32
Test: 16/16
Control: 16/16
7. Andersen et al,19 2017 RCT (Wohlfahrt et al
Continuum)
7 y 12/12
Test: 6/6
Control: 6/6
8. Roos-Jansaker et al,32,33,43
2007, 2011, 2014
Controlled clinical study Bone loss .3 threads ($1.8 mm) 1–4
intrabony defect + BOP and/or pus
5 y 25/45
Test: 13/23
Control: 12/22
9. Jepsen et al,20 2016 RCT PD $5 mm + BOP/pus + intraosseous
circumferential 3-wall defects $3 mm
depth, defect angle #35°
12 mo 63/63
Test: 33/33
Control: 30/30
10. Guler et al,25 2016 Controlled clinical study PD .5 mm + BOP/pus 6 mo 24/35
Test: 18/19
Class Ib defects (vestibular dehiscence +
circumferential bone resorption)
Control: 6/16
Class Ic defects (vestibular dehiscence +
circumferential bone resorption)
Class Id defects (circumferential bone
resorption)
11. Isehed et al,37 2016 RCT PD$ 5 mm + BOP/pus + angular bone loss
$ 3 mm
12 mo 29/29
Test: 15/15
Control: 14/14
(continued on next page)
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Table 1. (Continued)
Author Study Design Case Definition (Defect Type) Follow-up Period
No. of Patients/
Implants
12. Schwarz et al,21,44–46 2011,
2012, 2013, 2017
RCT PD $6 mm + BOP/pus intrabony
component . 3 mm + supracrestal
component .1 mm
7 y 15/15
Test: 6/6
Control: 9/9
13. Roccuzzo et al,38,47 2011,
2017
Controlled clinical study PD $ 6 mm + crater-like intrabony defects 7 y 26/26
Test: 12/12
Control: 14/14
Author Implant Type
Age Mean 6 SD,
(Range), y Sex, Female/Male Patient Smoking Status
1. Khoury and Buchmann
200134
IMZ and F2 implants (Friadent GmbH,
Mannheim, Germany)
48.2 6 6.3 22/3 No information
2. Deppe et al,39 2007 IMZ; Frialit-2, Brånemark implants, Nobel
Biocare, Straumann
No information No information No information
3. Schwarz et al,23,41,42 2006,
2008, 2009
Brånemark, Camlog, ITI (TPS and SLA),
MTX, TSV, ZL
54.4 6 12.5 y 14/8 1 patient light smoker (,10 cig./d)
4. Schwarz et al,26 2010 Brånemark, Camlog, ITI, TSV (Tapered
Screw Vent)
48.5 6 14.6 No information Included nonsmokers and light smokers
(,10 cig./d)
5. Aghazadeh et al,22 2012 Implamed, Nobel Biocare, Straumann,
TIUnite, nonidentified.
Test: 67.0 6 7.5 27/18 Smokers:
Test: 69.6%
Control: 70.1 6 6.2 Control: 40.9%
6. Wohlfahrt et al,18 2012 Astra Tech, Nobel Biocare (Nobel Mark III,
Nobel Replace), Straumann, Frialit
(Dentsply Friadent)
Test: 65.0 6 10.0 13/19 Smokers:
Test: 6 (37.5%)
Control: 57.2 6 12.3 Control: 10 (58.8%)
7. Andersen et al,19 2017 Test: 67 6 12.9 5/7 Smokers or former smokers: 10/12
patients (83%)Control: 67.2 6 11.8
8. Roos-Jansaker et al,32,33,43
2007, 2011, 2014
Brånemark implants Test: 64.9 6 7.5 14/11 Current smokers:
Test: 10 (76.9%)
Control: 65.7 6 7.4 Control: 8 (66.7%)
Former smokers:
Test: 2 (15.4%)
Control: 3 (25%)
Never smoked:
Test: 1 (7.7%)
Control: 1 (8.3%)
(continued on next page)
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Table 1. (Continued)
Author Implant Type
Age Mean 6 SD,
(Range), y Sex, Female/Male Patient Smoking Status
9. Jepsen et al,20 2016 Ankylos, Astra, Dyna, Friadent Xive, Nobel
Biocare, SIC Invent, Straumann, Tri-Max,
TMI; Zimmer, Biomet 3i
Test: 57.5 6 12.6
Control: 59.1 6 12.2
27/36 Current smokers:
Test: 11 (33.3%)
Control: 7 (23.3%)
Former smokers:
Test: 9 (27.3%)
Control: 11 (36.7%)
Nonsmokers:
Test: 13 (39.4%)
Control: 12 (40.0%)
10. Guler et al,25 2016 Zimmer, Adin Global, MIS-Implants, ITI,
Ankylos, Dentsply Friadent, Xive
(Dentsply), nonidentified
45.36 6 14.1 9/15 Light smokers included (,10 cig.7 d):
Test: 3 (18.75%)
Control: 3 (50%)
11. Isehed et al,37 2016 Nobel turned, Nobel TiUnite, Astra,
Straumann SLA, 3i
Test: median 70.0 (61–81) Test: 9/6 Current smokers:
Test: 4 (26.7%)
Control: 9/5 Control: 6 (42.9%)
Control: median
73.5 (67–83)
12. Schwarz et al,21,44–46 2011,
2012, 2013, 2017
Astra Tech, Brånemark, Nobel Biocare,
Camlog, ITI, KSI Bauer Schraube, REP
Nobel Replace, Tapered Screw Vent,
Zimmer, Dentsply Friadent, nonidentified
Median: 63 11/4 No information
13. Roccuzzo et al,38,47 2011,
2017
SLA and TPS Straumann 60 6 7.9 14/10 4 smokers (33%)
SLA, sandblasted and acid-etched; TPS, titanium plasma–sprayed.
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Table 2. Study and Patient Characteristics: Observational Studies
Author Study Design Case Definition (Defect Type) Follow-up Period
No. of Patients/
Implants
1. Behneke et al,35 2000 Prospective study PD .5 mm + progressive crater-like or saucer shape periimplant
bone defect
6 mo–3 y 17/25
2. Haas et al,36 2000 Observational study Signs of inflammation (redness, swelling, secretion) + BOP + PD .6
mm + progressive bone loss. Narrow vertical bone defects were
included
9.5 mo 17/24
3. Roos-Jansaker et al,32 2007 Case series Progressive bone loss of 3 threads (1.8 mm) or more after the first
year of healing + BOP/pus
12 mo 12/16
4. Romanos et al,29 2008 Case series Deep periimplant intrabony defects followed by bleeding and
periimplant pockets
27.10 (17.83) mo 15/19
5. Wiltfang et al,40 2010 Prospective case series Vertical bone loss $ 4 mm + circumferential crater defect with loss of
oral and vestibular bone
12 mo 22/36
6. Froum et al,17 2012 Case series PD $ 5 mm + BOP + bone loss $ 3 mm 2–10 y 100/170
7. Matarasso et al,30 2013 Prospective case series PD $ 5 mm + BOP + $ 2 mm of marginal bone loss or exposure of
$1 implant thread
12 mo 11/11
8. Schwarz et al,28 2014 Case series PD .6 mm + intrabony component . 3 mm + radiographic
supracrestal defect $ 1 mm
6 mo 10/13
Combined effects:
Class Ib (ie, buccal dehiscence + semicircular bone resorption to the
middle of the implant body)
Class Ie (ie, circular bone resorption under maintenance of the buccal
and oral compacta)
9. Roccuzzo et al,31 2016 Prospective case series Crater-like lesion + PD . 6 mm 12 mo 75/75
10. Rotenberg et al,24 2016 Retrospective case series PD $ 5 mm + BOP/pus + radiographic bone loss 12 mo 11/11
11. Nart et al,27 2017 Case series PD. 5 mm + BOP/Pus + 2-wall or 3dwall intrabony defects$3 mm
depth identified on intraoral radiographs
12 mo 13/17
Author Implant Type
Age, Mean 6 SD,
(Range), y Sex, Female/Male Patient Smoking Status
1. Behneke et al,35 2000 ITI screw implants 51.7 11/6 No information
2. Haas et al,36 2000 IMZ implants (Friadent, Mannheim, Germany) No information 13/4 No information
3. Roos-Jansaker et al,32 2007 Brånemark implants 64.4 6 6.0, (56–75) 9/3 Current smokers: 8 (66.7%)
Former smokers: 2 (16.7%)
Never smoked: 2 (16.7%)
4. Romanos et al,29 2008 Ankylos, ITI, IMZ implants 57.21 6 12.14 10/5 No information
5. Wiltfang et al,40 2010 Implant type not indicated Range (24–83) 12/10 No information
6. Froum et al,17 2012 Implant type not indicated 58.08, (20–83) 53/47 19 implants placed in smoking
patients, 151dnonsmokers
7. Matarasso et al,30 2013 Tissue-level sandblasted, acid-etched
surface implants (Straumann)
63.6 6 8.9 5/6 5 smokers (45%)/6 nonsmokers
(55%)
(continued on next page)
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1. Review papers, case reports, let-
ters, editorials, and abstracts on
in vitro and animal studies;
2. Studies not providing data on clin-
ical and/or radiographic data or
treatment protocols;
3. Studies not providing a definition
of periimplantitis;
4. Studies published not in interna-
tional peer-reviewed journal.
The initial electronic search re-
sulted in the identification of 1218 titles
(Fig. 1). At the first stage, 1187 publi-
cations were excluded based on the title
and abstract. At the second stage, the
remaining 31 full-text articles were
evaluated. The reasons for excluding
studies after full-text assessment were
as follows: retrospective studies,8,9
nonaugmentative surgical treatment
was performed (n ¼ 4),10–13 and infor-
mation on the augmentation protocol
was lacking (n¼ 1).14 Finally, 24 stud-
ies were identified for inclusion in the
review.
Data Collection
Data extraction templates were
used to retrieve general information on
the study design, periimplantitis case
definitions, follow-up periods, number
of implants and patients, implant type,
patient sex, age, and smoking status
(Tables 1 and 2). The treatment meth-
ods applied in the test and control
groups, the mode of healing (ie, sub-
merged or nonsubmerged), information
on the use of systemic antibiotics, and
clinical and/or radiographic treatment
outcomes are presented in Tables 3
and 4. The mean values and SDs of
BOP, PD values, radiographic bone
defect fill, or defect reduction after the
respective treatment were extracted for
the data analysis.
Information on further disease pro-
gression/treatment complications and
treatment success based on the criteria
that the authors used is presented in Ta-
bles 3–5.
Quality Assessment
The Cochrane Collaboration’s tool
for assessing risk of bias was used in the
case of controlled clinical trials.15
Methodological quality assessment of
the observational studies was based on
the Newcastle-Ottawa Quality Assess-
ment Scale forCohort studies16 (Table 6
and 7).
Data Synthesis
Due to the heterogeneity among the
studies regarding study designs, treat-
ment protocols applied, and outcome
variables, no quantitative analysis was
performed.
RESULTS
Presented inTables 1–4 are 13 com-
parative and 11 observational clinical
studies that reported on the surgical
treatment of periimplantitis by using
augmentative therapies. The follow-up
time ranged from 6 months to 7 years
for comparative studies and from 6
months to up to 2 to 1017 years for obser-
vational studies. Out of the 12 compara-
tive clinical studies included, 7 appeared
to be randomized controlled clinical tri-
als.18–23 All controlled clinical studies
were judged to have high to unclear risk
of bias (Table 6). The included observa-
tional studies scored between 5 and 7
stars (out of 9) based on the Newcastle-
Ottawa Scale (Table 7).
Patient Characteristics
Five hundred and ninety patients
were treated with the augmentative
surgical approach. The mean age of
the patients ranged from 45.36 to 70.1
years. Seventeen studies (10 controlled
and 7 observational studies) reported on
the smoking statuses of the patients.
Particularly, although one observa-
tional study included only nonsmoking
patients,24 5 investigations (3 con-
trolled23,25,26 and 2 observational27,28)
involved both nonsmokers and light
smokers (,10 cig./d). In the rest of
the controlled and observational stud-
ies, the number of smokers ranged from
23.3% to 76.9%, and from 15% to
66.7%, respectively (Tables 1 and 2).
Implant Characteristics
In total, 840 implants of various
surfaces (379 in controlled and 417 in
observational studies) were included in
the review. Although the majority of the
implants had moderately rough surfaces
(5 controlled18–20,22,25 and 5 observa-
tional24,27,29–31 studies), 2 studies were
conducted with smooth-surface implants
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Table 3. Treatment Protocols, Outcomes, and Complications: Comparative Studies
Treatment
Author Presurgical Therapy
Decontamination of Implant
Surface Grafting Material Membrane
Submerged/
Nonsubmerged
Healing Systemic Antibiotics
1. Khoury and
Buchmann
2001
6 mo before surgery
nonsurgical implant
scaling + irrigation with
chlorhexidine (0.2%)
Test 1: 0.2% chlorhexidine
digluconate, citric acid (pH ¼
1) (1 min) and rinsed with H2O2
and 0.9% saline
Test 2: 0.2% chlorhexidine
digluconate, citric acid (pH ¼ 1)
(1 min) and rinsed with H2O2
and 0.9% saline
Control: 0.2% chlorhexidine
digluconate, citric acid (pH ¼ 1)
(1 min) and rinsed with H2O2
and 0.9% saline
Autogenous bone Nonresorbable
membrane
Resorbable membrane
No membrane
Submerged Antibiotics administered 4 wk
before surgery (for 1 wk),
and later starting 1 d and
finishing 7 d after surgery
according to the individual
susceptibility test results
2. Deppe et al,
2007
Presurgical chlorhexidine
application (0.3%) for 3
wk
Test: air polishing + CO2 laser
(cw mode, 2.5 W, 12 3 5 s)
Control: air polishing
Beta tricalcium
phosphate
combined with
autogenous bone
chips harvested
from the retromolar
area (50:50)
Nonresorbable
membrane
4 mo submerged No
3. Schwarz
et al, 2006,
2008, 2009
OHI + nonsurgical therapy Test: mechanical debridement
(plastic curettes)
Nanocrystalline
hydroxyapatite
paste
No membrane Non-submerged No
Control: mechanical debridement
(plastic curettes)
Bovine-derived
xenograft
Native collagen barrier
membrane
4. Schwarz
et al, 2010
Nonsurgical therapy using
Er:YAG laser 4 wk
before surgery
Mechanical debridement (carbon
curettes) + decontamination
with cotton pellets soaked in
the sterile saline
Bovine-derived
xenograft
Native collagen barrier
membrane
Non-submerged No
Test: Class Ib°, Class Ic°°
Control: Class Ie°°°
5. Aghazadeh
et al, 2012
OHI Test: mechanical debridement
(titanium instruments) +
decontamination using H2O2
(1 min)
Bovine-derived
xenograft
Resorbable synthetic
barrier membrane
Non-submerged Postoperative antibiotics
Azithromycin 2 3 250 mg
1 d, 1 3 250 mg 2–4 d
Control: mechanical debridement
(titanium instruments) +
decontamination using H2O2
(1 min)
Autogenous bone
chips harvested
from the mandibular
ramus region
(continued on next page)
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Table 3. (Continued)
Treatment
Author Presurgical Therapy
Decontamination of Implant
Surface Grafting Material Membrane
Submerged/
Nonsubmerged
Healing Systemic Antibiotics
6. Wohlfahrt
et al, 2012
NR Test: titanium curettes and 24%
ethylenediaminetetraacetic
acid gel (2 min)
Titanium granules No membrane 6 mo submerged Amoxicillin (500 mg 3 times/d)
and metronidazole (400 mg
2 times/d) starting 3
d before surgery and
continuing 7 d after the
surgery
Control: titanium curettes and
24% ethylenediaminetetraacetic
acid gel (2 min)
Open-flap surgery
7. Andersen
et al, 2017
(Continuum
Wohlfahrt
et al, 2012)
NR Test: titanium curettes and 24%
ethylendiaminetetraacetic acid
gel (2 min)
Titanium granules No membrane Amoxicillin (500 mg 3 times/d)
and metronidazole (400 mg
2 times/d) starting 3
d before surgery and
continuing 7 d after the
surgery
Control: titanium curettes and
24% ethylenediaminetetraacetic
acid gel (EDTA) (2 min)
Open-flap surgery 6 mo submerged
8. Roos-
Jansaker
et al, 2007,
2011, 2014
NR Test: H2O2 (3 min) Algae-derived
xenograft
Resorbable synthetic
membrane
Non-submerged Amoxicillin 375 mg x 3 per d +
metronidazole 400 mg x 2
per d, 10 d after the
surgery
Control: H2O2 (3 min) No membrane
9. Jepsen et
al, 2016
1 mo before surgery OHIˣ
+ nonsurgical
periodontal/periimplant
cleaning
Test: rotary titanium brush
and 3% H2O2 (1 min)
followed by rinsing with
saline (60 s)
Titanium granules No membrane Non-submerged Amoxicillin 500 mg
3 times/d + metronidazole
400 mg 2 times/d, 8 d,
starting 1 d before
surgery
Control: rotary titanium brush
and 3% H2O2 (1 min)
followed by rinsing with saline
(60 s)
Open-flap surgery
(continued on next page)
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Table 3. (Continued)
Treatment
Author Presurgical Therapy
Decontamination of Implant
Surface Grafting Material Membrane
Submerged/
Nonsubmerged
Healing Systemic Antibiotics
10. Guler et al,
2016
OHI + mechanical
nonsurgical cleaning
Test: rotating titanium brush Titanium granules PRF (platelet-rich fibrin
membrane)
Non-submerged Amoxicillin clavulanate 2 3
1000 mg/d, 7 d
Control: rotating titanium brush Xenograft Resorbable collagen
membrane + PRF
(platelet-rich fibrin
membrane)
11. Isehed
et al, 2016
OHI Test: mechanical ultrasonic and
titanium hand instruments
cotton gauze–soaked in
sodium chloride
Emdogain (0.3 ml) No membrane Non-submerged No
Control: mechanical ultrasonic
and titanium hand instruments
cotton gauze–soaked in
sodium chloride
Open-flap surgery
12. Schwarz
et al, 2011,
2012,
2013, 2017
Initial nonsurgical therapy
+ OHI
Test: Er:YAG laser device (cone-
shape glass fiber tip) at 11.4 J/
cm2 implantoplasty at buccally
and supracrestally exposed
implant parts
Bovine-derived
xenograft
Native collagen
membrane
Non-submerged No
Control: open-flap surgery +
mechanical debridement
(plastic curette) +
decontamination (cotton
pellets soaked in saline)
implantoplasty at buccally and
supracrestally exposed
implant parts
13. Roccuzzo
et al, 2011,
2017
Professional implant
cleaning + OHI
Test: SLA surface implants
(plastic curettes) +
decontamination (24% EDTA
and 1% CHX gel)
Bovine-derived
xenograft
No membrane Non-submerged 1 g of amoxicillin + clavulanic
acid 2 times/d, 6 d
Control: TPS surface implants
(plastic curettes) +
decontamination (24% EDTA
and 1% CHX gel)
(continued on next page)
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Table 3. (Continued)
Treatment Outcomes
Author PD Changes (mm) (SD); (Range) BOP Changes (%) (SD); (Range) Radiographic Outcomes
Further Disease Progression/
Complications
1. Khoury and
Buchmann 2001
Implant level
Test 1: 5.4 (3.0)
NR Radiographic vertical intrabony
defect height reduction (mm):
2.8 (3.1)
17 out of 29 barrier-treated
implants (58.6%) were
compromised by early
posttherapy complication (eg,
dehiscence, exposure, fistula,
or sequester formation)
Test 2: 2.6 (1.6) 1.9 (3.2)
Control: 5.1 (2.7) 2.4 (2.7)
Significant improvement
compared to baseline in all
groups (P . 0.001).
Significantly less improvement
in test 2 group compared to
baseline (P ¼ 0.102).
Significantly less improvement in
test 2 group compared to test
1 and the control (P # 0.05)
No difference among the groups
(P # 0.05).
2. Deppe et al, 2007 Implant level
Test: baseline: 5.0 (1.3), after
5 y: 2.5 (1.4).
NR Radiographic DIB (distance from
the implant shoulder to the first
bone contact):
Test group: 4 implants were lost
due to a chronic inflammation
4.5 (1.2) mm Control group: 4 implants were
lost due to a severe infection
developed within first weeks
after surgery
Control: baseline: 4.8 (1.4), after
5 y: 2.5 (1.1).
4.7 (1.1) mm
No significant difference between
the groups
No significant difference between
the groups
3. Schwarz et al,
2006, 2008, 2009
Subject level NR After 12 mo, 2 patients had to be
discontinued due to severe pus
formation.
Test: 1.1 (0.3) 32
Control: 2.5 (0.9) 51
Significantly higher at control
sites
Significantly higher at control sites
4. Schwarz et al,
2010
Ib: 1.6 (0.9) Ib: 38.9 (16.6) NR None
Ic: 1.6 (0.7) Ic: 25.9 (16.7)
Ie: 2.7 (16.7) Ie: 61.1 (16.7)
Significant improvement
compared to baseline (P ,
0.001)
Significant improvement
compared to baseline (P ,
0.001)
Ie group tended to reveal
higher mean PD
reduction
Significantly higher BOP
reduction in Ie group
5. Aghazadeh et al,
2012
Implant level Mean radiographic bone defect fill
(mm):
None
Test: 3.1 (0.2) 50.4 (5.3) 1.1 (0.3)
Control: 2.0 (0.2) 44.8 (6.3) 0.2 (0.3)
Significantly higher in the test
group (P , 0.01)
No significant difference between
the groups
Significantly higher in test group
(P , 0.05)
(continued on next page)
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Table 3. (Continued)
Treatment Outcomes
Author PD Changes (mm) (SD); (Range) BOP Changes (%) (SD); (Range) Radiographic Outcomes
Further Disease Progression/
Complications
6. Wohlfahrt et al,
2012
Implant level
Test: 1.7 (1.7); (−2.3, 4.3)
Control: 2.0 (2.3); (−1.5, 6.5)
0.38 (2.1); (−2, 6)
0.56 (2.9); (−5, 6)
Radiographic defect height
reduction (mm):
Further progression of bone loss:
2.0 (1.7); (−0.9, 5.2) Test: 4 implants
Mean radiographic intrabony
defect fill (%): 57.0 (45.1);
(−33.9, 167.6)
Control: 7 implants
Radiographic defect height
reduction (mm): 0.1 (1.9); (-5.7,
5.2)
Between-group comparison:
Significantly higher in test
group
Significant improvement
compared to baseline (P ,
0.001)
Not significant improvement
compared to baseline
Mean radiographic
intrabony defect fill (%): −14.8
(83.4); (-278.7, 84.6)
significantly higher in test
group.
No significant difference between
the groups (P ¼ 0.66)
No significant difference between
the groups (P ¼ 0.60)
7. Andersen et al,
2017
(Continuum
Wohlfahrt et al,
2012)
Test: baseline: 6.5 (1.9),
after 7 y: 4.3 (2.4)
At least one BOP-positive site
(out of 6):
5 implants
Mean radiographic osseous
defect fill (mm):
1.92 (2)
Implant loss:
Test group: 3 implants (one
implant due to the technical
complications)
Control: baseline: 6.5 (2.3),
after 7 y: 3.5 (1.2)
5 implants 1.3 (1.4)
8. Roos-Jansaker
et al, 2007, 2011,
2014
Implant level NR Radiographic defect fill (mm): Progressive periimplantitis (bone
loss $1.0 mm + BOP) in 5 y
period detected in 2.2% of
implants
PD reduction at the deepest site
(mm)
Test: 3.0 (2.4) 1.5 (1.2)
Control: 3.3 (2.0) 1.1 (1.2)
No significant difference between
the groups (P ¼ 0.60)
No significant difference between
the groups (P ¼ 0.249)
(continued on next page)
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Table 3. (Continued)
Treatment Outcomes
Author PD Changes (mm) (SD); (Range) BOP Changes (%) (SD); (Range) Radiographic Outcomes
Further Disease Progression/
Complications
9. Jepsen et al, 2016 Implant level Radiographic defect height
reduction (mm):
None
Test: 2.8 (1.3) 56.1 (30.5) Mesial/distal: 3.61 (1.96)/3.56
(2.07)
Mean radiographic intrabony
defect fill (%):
Mesial/distal: 79.00 (29.85)/74.22
(36.33)
Control: 2.6 (1.4) 44.9 (38.2) Radiographic defect height
reduction (mm):
Mesial/distal: 1.05 (1.42)/1.04
(1.34)
Significantly higher in test
group
Mean radiographic intrabony
defect fill (%):mesial/distal:
Significant reduction compared
to baseline (P , 0.001)
Significant reduction compared
to baseline (P , 0.001)
23.11 (46.28)/21.89 (30.16)
No significant difference between
groups
No significant difference between
groups
Significantly higher in test group.
10. Guler et al, 2016 Implant level
Test: baseline: 5.28 (1.06),
after 6 mo: 3.34 (0.82)
Baseline: 50.17 (25.19)%,
after 6 mo: 24.32 (11.22) %
Mean radiographic
bone defect fill (mm):
1.74 (0.65)
In control group, collagen
membrane was exposed in 2
patients
Control: baseline: 4.72 (1.02),
after 6 mo: 3.18 (0.54)
Baseline: 63.51 (24.38)%, after 6
mo: 33.00 (15.51)%
1.05 (0.54)
11. Isehed et al, 2016 Test: 2.8
Control: 3.00
BOP decreased from
approximately 90% to 30%,
but relapsed to nearly 70%
at 12-mo.
Marginal bone level changes (mm):
Test: increased: 0.9
Control: decreased: 0.1
Two patients were treated with
systemic antibiotics at 3-mo
follow-up due to severe infection.
One implant disintegrated in the
control group.
Did not differ from baseline to
12 mo between the groups.
Did not differ from baseline to 12
mo between the groups.
(continued on next page)
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(one observational32 and one compara-
tive study33), and 3 studies (one compar-
ative34 and 2 observational35,36 studies)
focused on rough-surface implants
only. Seven investigations included
both smooth, rough, and moderately
rough,21,23,26,28,37 or rough and moder-
ately rough38,39 implants. Two observa-
tional studies didnot provide information
on the surfaces of the implants.17,40
Case Definitions
Definitions of the periimplantitis
cases selected for the augmentative
treatment varied widely among the
included studies (Tables 1–4). Except
for the 2 studies, where periimplantitis
diagnosis was based only on radio-
graphical evaluation,34,40 the rest of
the investigations defined periimplanti-
tis by the presence of BOP and/or PD
.5 mm, and radiographic bone loss. In
addition, the majority of the cases pre-
sented intrabony periimplant defect
configurations.18–23,25–29,31,33–40
Comparison of Augmentative and
Nonaugmentative Approaches
Three RCTs assessed the clinical
efficacy of augmentative therapy over
the OFD approach alone.18–20 Two
studies included the same patient sam-
ple and reported the treatment outcomes
at 12 months and 7 years of follow-
up.18,19 At 12 months after the treat-
ment, two 1-year clinical investigations
demonstrated a significantly higher per-
centage of radiographic fill of the in-
trabony defect treated with titanium
granules when compared to nonaug-
mentative treatment.18,20 However, the
clinical treatment outcomes, in terms of
PD and BOP reduction, did not differ
between the 2 treatment approaches
at both 12-month and 7-year follow-
up.18–20 In the 7-year investigation,
due to the small number of the patients
(6 test and 6 control), statistical analysis
between the groupswasnot performed.19
Nevertheless, the results indicatedamin-
imal difference in osseous defect depth
changes between the groups.19
Characteristics of Interventions
Decontamination. Methods to decon-
taminate the implant surface included
mechanical,17,20,21,23–25,30,35,37,39
chemical,17–19,22,31–34,38,40 laser
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Table 4. Treatment Protocols, Outcomes and Complications: Observational Studies
Author Treatment
Presurgical Therapy
Decontamination of
Implant Surface Grafting Material Membrane
Submerged/
Nonsubmerged Healing Systemic Antibiotics
1. Behneke et al,
2000
1-mo before surgery
local-disinfecting
treatment using weekly
submarginal irrigation
with iodine solution
Air-powder abrasive with
sodium carbonate (30
s) + rinse with sterile
saline
Autogenous block-shape
(18 implants) or
particulate bone grafts
(7 implants)
No membrane Nonsubmerged Metronidazole 4003 2 for
7 d
2. Haas et al, 2000 NR Toluidine blue O (1 min)
and soft laser light
(wave length 906 nm)
Particulate autogenous
bone
Nonresorbable e-PTFE
membrane
Submerged Augmentin (5 d)
3. Roos-Jansaker
et al, 2007
NR H2O2 (3%) Nonbovine-derived bone
substitute
Resorbable membrane Submerged Amoxicillin (375 mg x 3) +
metronidazole (400 mg
x 2) for 10 d, starting 1
d before surgery
4. Romanos et al,
2008
NR CO2 laser
decontamination
Particulate autogenous
bone (10 implants)/or
bovine-derived
xenograft (9 implants)
Resorbable collagen
membrane
12 submerged, 7
nonsubmerged, 12
submerged
No
5. Wiltfang et al,
2010
Mechanical implant
cleaning + periimplant
pocket irrigation with
chlorhexidine (0.12%)
(3 times a week)
Etching gel (Gluma Etch
20 Gel)
Autogenous bone and
demineralized
xenograft (1:1)
containing native bone
morphogenetic protein
(BMPs) and vascular
endothelial growth
factor
No membrane Non-submerged Prophylactic antibiotics
(amoxicillin/sulbactam)
were given
perioperatively
6. Froum et al,
2012
1 mo before surgery full-
mouth debridement +
OHI
Pellets soaked in
minocycline (50 mg/ml)
and 0.12%
chlorhexidine gluconate
(CHX) (for 45–60 s) +
air-powder abrasive +
saline spray +
application of EMD
(Emdogain) or PDGF
(platelet-derived growth
factor)
Mineralized freeze-dried
bone allograft
Resorbable membrane
and/or subepithelial
connective tissue graft
Non-submerged No
7. Matarasso et al,
2013
OHI + motivation +
nonsurgical mechanical
cleaning and polishing
8–10 wk before the
surgery
Implantoplasty at
suprabony exposed
implant parts + air-
abrasive with glycine
powder for intrabony
defect (30 s) + rinsed
with saline solution
(30 s)
Deproteinized bovine
bone mineral
Resorbable membrane Non-submerged Amoxicillin 875 mg +
clavulanic acid 125 mg,
5 d.
(continued on next page)
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Table 4. (Continued)
Author Treatment
Presurgical Therapy
Decontamination of
Implant Surface Grafting Material Membrane
Submerged/
Nonsubmerged Healing Systemic Antibiotics
8. Schwarz et al,
2014
Nonsurgical therapy using
Er:YAG laser 2 wk
before surgery
Implantoplasty at buccally
and supracrestally
exposed implant parts
+ decontamination of
unmodified surface
with plastic curettes
and cotton pellets
soaked in saline
Bovine-derived xenograft Native collagen
membrane at intrabony
components +
connective tissue graft
on the buccal aspect
Non-submerged Amoxicillin 2 3 1000 mg/
d (in case of allergy:
Clindamycin 2 3 600
mg/d) 1 h before and 5
d postoperatively
9. Roccuzzo et al,
2016
OHI + scaling and root
planning of teeth and
cleaning of implant
shoulders
Mechanical
decontamination with
titanium curettes and
titanium brush in deep
narrow pockets +
EDTA 24% (2 min) +
CHX gel (1%) (2 min)
Deproteinized bovine
bone mineral with 10%
collagen
+/− in case of no
keratinized tissue,
connective tissue graft
from the tuberosity are
Non-submerged 1 g of amoxicillin +
clavulanic acid x 2,
starting 1 h before
surgery, 6 d
10. Rotenberg
et al, 2016
NR Mechanical debridement
with titanium-coated
curettes and plastic-
tipped ultrasonic
instrument + CHX
(0.12%) soaked gauze
applied (2 min)
Collagen-coated bovine
bone
No membrane Non-submerged Amoxicillin 500 mg x 3 or
300 mg clindamycin x 4
11. Nart et al, 2017 OHI + supragingival and
subgingival mechanical
debridement 6 wk
before surgery
Mechanical debridement
with stainless steel
curette + implantoplasty
supracrestally +
intrabony defect
debrided with ultrasonic
device + 3% H2O2
(1 min) + rinsed with saline
50% particulated
mineralized cancellous
allograft impregnated
with trombomycine and
50% impregnated with
vancomycin
Collagen membrane Non-submerged No
Treatment Outcomes
PD Changes (mm) (SD);
(Range)
BOP Changes (%) (SD);
(Range) Radiographic Outcomes
Further Disease Progression/
Complications
1. Behneke et al, 2000 Implant level
Median reduction: 3.3 mm
after 3-y
NR Radiographic mean bone defect
fill (mm): 3.7
Treatment failure (explanation) in
6 patients
Median defect depth reduction
(mm) at re-entry surgery:
6.9–0.7
Bone repair: 90%.
(continued on next page)
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Table 4. (Continued)
Treatment Outcomes
PD Changes (mm) (SD);
(Range)
BOP Changes (%) (SD);
(Range) Radiographic Outcomes
Further Disease Progression/
Complications
2. Haas et al, 2000 NR NR Radiographic mean defect fill
(implant level):
Exposure of the membrane
occurred un all patients after
a mean of 3 wk postoperative.
2 (1.9) mm, (36.4%) 2 implants failed and had to be
removed
3. Roos-Jansaker et al, 2007 Implant level
4.2 (1.5); (2–7)
NR Radiographic mean bone defect
fill (mm):
2.3 (1.2); (0.6–5.1)
2 wk after postoperative
membrane exposure occurred
in 31.3% of implant areas
4. Romanos et al, 2008 Implant level
Baseline PD (mm): 6.00 (2.03),
After treatment: 2.48 (0.63)
Baseline bleeding index:
2.76 (0.35), after
treatment: 1.03 (0.85)
Complete radiographic bone fill
found in all defects after the
xenogenic bone graft, in sites
treated with autogenous bone
graft, at least 2/3 of the defect
was filled.
None reported
Reduced significantly compared
to baseline (P . 0.01)
Reduced significantly compared
to baseline (P . 0.01)
5. Wiltfang et al, 2010 Implant level
Reduction of PD (mm):
4 (95% CI: 3.3–4.6)
Baseline: 61%,
after 12 mo: 25%
Radiographic mean bone defect
fill (mm): 3.5 (95% CI: 2.7, 4.3)
1 implant (3%) was lost due to
mobility
6. Froum et al, 2012 Implant level:
5.10 (2.20): 2–12
91.1% Mean radiographic bone gain
(mm): 1.77 (1.99)
2 implants were lost due to
a disease progression
18 implants required 1 additional
surgery and 10 implants
required 2 additional surgeries
to achieve the desired
outcome7. Matarasso et al, 2013 Implant level
Baseline: 8.1 (1.8), after 12 mo:
4.0 (1.3).
Baseline: 19.7 (40.1), after 12
mo: 6.1 (24.0)
Radiographic marginal bone level
changes (mm):
2 implants displayed early
membrane exposure
Baseline: 8.0 (3.7), after 12 mo:
5.2 (3.0). Significant decrease
(P , 0.001).
Radiographic mean bone defect
fill: 93.3 (13.0) %
Significant reduction compared
to baseline (P ¼ 0.032).
Significant reduction compared
to baseline (P ¼ 0.001).
Radiographic depth of intrabony
defect (mm):
Baseline: 3.5 (3.5), after 12 mo:
0.5 (13.0)
Significant reduction (P , 0.001)
8. Schwarz et al, 2014 Implant level 74.39 (28.52) NR None reported
(continued on next page)
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therapy,21,26,28,29,39 or their combina-
tions (Tables 3 and 4). In addition, one
comparative and 3 observational stud-
ies, in adjunct to mechanical,21,27,28 air-
powder abrasive,30 or laser (Er:YAG)21
decontamination methods, involved the
performance of implantoplasty to supra-
crestally and buccally exposed implant
parts.
Comparative studies
When considering the effective-
ness of different implant surface
decontamination protocols after aug-
mentative periimplantitis surgery,
Deppe et al39 did not find a difference
between the use of a carbon dioxide
laser and air polishing on a long-
term basis (5 years) in terms of the
clinical attachment, PD, and radio-
graphic marginal bone level changes.
Moreover, clinical outcomes (eg, clin-
ical attachment gain andBOP reduction)
obtained by using laser decontamina-
tion (Er:YAG) were comparable with
theconventionaldecontamination(plas-
tic curettes + cotton pellets soaked
in saline) approaches as demon-
strated in the findings of the 7-year
investigation.21
Augmentation protocols.
Bone substitutes alone
Four observational24,31,35,40 and one
controlled clinical study38 reported on
augmentative periimplantitis treatment
using bone substitute materials without
a barrier membrane. Besides, 3 compara-
tive studies included control groups trea-
tedwithbonefiller alone.23,33,34Avariety
of bone replacement materials were
applied (autogenousbone,34,35 alloplastic
bone filler,23 and xenograft24,31,33,38).
Moreover, in 4 controlled clinical studies,
intrabony periimplant defects were filled
using titanium granules.18–20,25
Guided bone regeneration
The guided bone regeneration
concept including the application of
a bone substitute material and a bar-
rier membrane was performed in 7
observational17,27–30,32,36 and 8
comparative studies.21–23,25,26,33,34,39
Resorbable17,21–23,25–30,32–34 and nonre-
sorbable34,36,39 membranes were used.
In addition to the use of a collagen
membrane, in one observational study,
connective tissue graft was placed on
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the buccal aspect of the implant, which
at the 6-month follow-up was associ-
ated with minimal mucosal height
changes.28
Addition of biologically active materials
Addition of biologically active ma-
terials were applied in 2 observational
(enamel matrix derivative [EMD] or
platelet-derived growth factor,17
and xenograft containing native bone
morphogenetic protein and vascular
endothelial growth factor40) and 2
Table 5. Success of the Surgical Augmentative Treatment Indicated in the Studies
Author Definition of Treatment Success Treatment Success
Jepsen et al,20
2016
Complete disease resolution: PD #4 mm, no BOP at 6
implant sites and no further bone loss
30% (10/33) of implants
Schwarz
et al,21 2017
Absence of BOP Test: 4 out of 6 patients
Control: 5 out of 9 patients
Total: 9/15 patients (60%)
Roccuzzo
et al,38 2017
PD , 5 mm, no BOP or pus, no further bone loss Test: 7/12 (58.3%) implants
Control: 2/14 (14.3%) implants
Significantly higher success in the test group
(P ¼ 0.04)
Aghazadeh
et al,22 2012
Successful treatment outcome PD #5 mm,
allowing for one site with BOP, no pus,
and gain or no loss of alveolar bone
Successful treatment outcome defined by
PD # 5 mm, no BOP, no pus (at any
implant surface), and gain or no loss of
alveolar bone
Test: 38.5% implants
Control: 13.9% implants
The likelihood of treatment success was
higher in the test group (LR: 3.2, 95%
CI: 1.0–10.6, P , 0.05)
Test: 8 implants (20.5%)
Control: 4 implants (11.1%)
Roos-Jansaker
et al,33 2014
Successful treatment:
radiographic evidence of $25% bone fill, but
independent of PD or BOP
radiographic evidence of $25% bone fill, PD #5 mm,
but independent of bleeding score
radiographic evidence of $25% bone fill, PD #5 mm,
bleeding of probing score #1
66.7% (30/45) implants
62.2% (28/45) implants
51.1% (23/45) implants
Table 6. Assessment of the Risk of Bias for Included Controlled Clinical Studies
Author
Random
Sequence
Generation
Allocation
Concealment Blinding
Incomplete
Outcome Data
Selective
Reporting
Other
Bias
Summary
Assessment
Khoury and Buchmann, 200134 † † † † * * Unclear
Deppe et al,39 2007 † † † * † * Unclear
Schwarz et al,23,41,42 2006,
2008, 2009
* † * ‡ † * Unclear
Schwarz et al,26 2010 † † † * * * Unclear
Aghazadeh et al,22 2012 † * ‡ * * * Unclear
Wohlfahrt et al,18 2012 † * * * * * Unclear
Andersen et al,19 2017 † * * ‡ ‡ ‡ Unclear
Roos-Jansaker et al,32,33,43
2007, 2011, 2014
† † † ‡ † * Unclear
Jepsen et al,20 2016 * * * ‡ * * High risk
Guler et al,25 2016 † † ‡ * * * Unclear
Isehed et al,37 2016 ‡ * * * * * High risk
Schwarz et al,44–46,21 2011,
2012, 2013, 2017
‡ † † † † * Unclear
Roccuzzo et al,38,47 2011, 2017 † † ‡ ‡ † * Unclear
*Low risk.
†Unclear risk.
‡High risk.
RAMANAUSKAITE ET AL IMPLANT DENTISTRY / VOLUME 28, NUMBER 2 2019 205
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
controlled clinical trials (platelet-rich
fibrin [PRF] membranes25 and
EMD37). In addition, one observational
study used allogenic bone substitutes
impregnated in antibiotics.27
Comparative studies
Type of bone filler. Surgical treatment
outcomes using different bone filler
materials were compared in the 3 clin-
ical studies.22,23,25 Accordingly, after
12 months of healing, significantly
higher radiographic bone level gain
and mean BOP and PD reduction were
obtained with the use of xenograft in
comparison to autogenous bone.22
However, when interpreting these re-
sults it should be taken into consider-
ation that xenogenic bone is more
radiopaque than autogenolus bone.
Furthermore, improved clinical out-
comes, in terms of BOP and PD reduc-
tion, were noted for slowly resorbing
bovine-derived minerals over
hydroxyapatite particles.23 Increased
radiographic bone defect fill was de-
tected in the sites treated with the
porous titanium granules compared to
xenograft, while the clinical outcomes
(ie, PD reduction and clinical attach-
ment changes [CAL]) did not differ
between the groups.25
Adjunctive use of barrier membrane.
Augmentative periimplantitis treat-
ments with and without a barrier
membrane were evaluated in 3 com-
parative studies.23,33,34 The mean
radiographic fill of an intrabony
defect obtained by the use of autoge-
nous bone and a nonresorbable mem-
brane was indicated to be 2.8 mm,
followed by the use of autogenous
bone alone (2.4 mm), and amounted
to 1.1 mmwhen autogenous bone par-
ticles were applied in conjunction
with a resorbable membrane.34 The
comparison among the 3 investigated
groups did not reach a significant
difference.34 These findings corrobo-
rate the data presented in the 5-year
investigation, where the additional
use of a resorbable membrane did
not improve the treatment outcome.33
On the contrary, a 4-year clinical
study revealed better clinical out-
comes when a combination of bone-
grafting material and a membrane
were used in comparison to the use
of grafting material alone.23
Addition of biologically active materi-
als. The results of RCT, that attempted
to evaluate the effect of EMD for the
management of periimplantitis com-
pared to OFD, showed that the use of
EMDdid not result in improved PD and
BOP after 12 months, but was associ-
ated with increased marginal bone level
Table 7. Assessment of the Risk of Bias for Included Observational Studies
Author
Selection (Max 4*)
Representativeness
of the Sample
Selection of
Nonexposed
Cohort
Ascertainment
of Exposure
Demonstration of the Outcomes
of Interest was Not Present
at Start of the Study
1. Behneke et al, 2000 * *
2. Haas et al, 2000 * *
3. Roos-Jansaker et al, 2007 * *
4. Romanos et al, 2008 * *
5. Wiltfang et al, 2010 * *
6. Froum et al, 2012 * *
7. Matarasso et al, 2013 * *
8. Schwarz et al, 2014 * *
9. Roccuzzo et al, 2016 * *
10. Rotenberg et al, 2016 * *
11. Nart et al, 2017 * *
Author
Comparability (max 2*) Outcome (max 3*)
Total
Comparability of Cohorts
on the Basis of the
Design or Analysis
Ascertainment
of Outcome
Was Follow-up
Long Enough for
Outcomes to Occur?
Adequacy of
Follow-up
of Cohorts
1. Behneke et al, 2000 * * * 5*
2. Haas et al, 2000 * * * 5*
3. Roos-Jansaker et al, 2007 ** * * * 7*
4. Romanos et al, 2008 * * * * 6*
5. Wiltfang et al, 2010 * * * * 6*
6. Froum et al, 2012 ** * * * 7*
7. Matarasso et al, 2013 ** * * * 7*
8. Schwarz et al, 2014 ** * * * 7*
9. Roccuzzo et al, 2016 ** * * * 7*
10. Rotenberg et al, 2016 ** * * * 7*
11. Nart et al, 2017 ** * * * 7*
Newcastle-Ottawa Quality Assessment Scale (Max 9*).
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and increased prevalence of Gram
+/aerobic bacteria.37
Healing Mode and Systemic Antibiotics
Submerged postoperative healing
was performed in 4 controlled18,19,34,39
and 2 observational studies.32,36 One
observational study included both heal-
ing modes.29
Systemic antibiotics were pre-
scribed in 15 studies, except 5 con-
trolled21,23,26,37,39 and 3 observational
studies.17,29,40 Preoperative prophylactic
antibiotics were used in one observa-
tional study.40 None of the included
studies compared neither the potential
influence of modes of healing (ie, non-
submerged vs submerged) nor the effect
of additional systemic antibiotics after
periimplantitis augmentative therapy.
Clinical and Radiographic
Treatment Outcomes
Augmentative periimplantitis ther-
apy was shown to result in significant
improvements in BOP20–23,26–28,30,31,38
and PD values18,20–31,33,34,38 in compar-
ison to the baseline. In particular, the
mean BOP reduction ranged from
25.9%25 to 89.99%21 and 91%17 in 1-
to 7-year period, and themeanPDreduc-
tion ranged from 0.7421 to 5.4 mm.34
The reported mean radiographic
fill of the intrabony defect ranged
between 57%18 and 93.3%.30 In addi-
tion, the radiographic reduction of the
intrabony defect height varied from
0.222 and 2.8 mm,34 up to 3.7035 and
3.77 mm.27
Success of Augmentative Therapy
Composite outcomes for the treat-
ment success were indicated in 5 of the
studies (Table 5). Depending on the cri-
teria that was applied, treatment success
ranged between 11% and 38.5% of the
implants in a 1-year period20,22 and
between 14.3% 38 and 66.7%33 of the
implants, and 60% of the patients,21 in
the long-term investigations (5–7 years).
Further Disease Progression and
Other Complications
Despite the successful clinical and
radiographic clinical performance of aug-
mentative therapies, casesof implant loss,
disease recurrence, and further progres-
sion were reported17–19,21,23,31,33,35,37–40
(Tables 3 and 4). Exposure of the barrier
membrane (nonresorbable34,36 and re-
sorbable25,30,32), fistula, or sequester for-
mation were reported in 58.6% of the
caseswhenbarriermembrane (resorbable
and nonresorbable) was used.34.
Factors Influencing Augmentative
Treatment Outcomes
The clinical outcomes of surgical
augmentative therapy were reported to
be influenced by the implant surface
characteristics,38 aswell as by theperiim-
plant defect configuration.26 Particularly,
moderately rough surface implants dem-
onstrated superior clinical treatment out-
comes in comparison to rough surface
implants,38 and circumferential-type de-
fectswere shown to perform in a superior
manner in conjunction with a dehis-
cence-type defect.26
CONCLUSIONS/RECOMMENDATIONS
• Surgical augmentative periimplanti-
tis therapy resulted in improved clin-
ical and radiographic treatment
outcomes compared to the baseline
in the majority of studies with 6
months to 7 to10years of follow-up.
• Augmentative surgical techniques
with the application of the titanium
granules did not demonstrate supe-
rior clinical treatment outcomes
whencompared to anonaugmenta-
tive approach (3 RCTs).
• There is no evidence to support
the superiority of a specific mate-
rial, product, or membrane in
terms of long-term clinical treat-
ment benefits.
• The method of implant surface
decontamination did not influence
the clinical outcomes of surgical
augmentative periimplantitis ther-
apy (1 RCT and 1 controlled com-
parative study).
• Clinical augmentative treatment
outcomes were shown to be influ-
enced by factors such as periim-
plant bone defect morphology
and implant surface characteristics
(2 controlled clinical studies).
• Due to the lack of comparative
studies, no clinical recommenda-
tions can be given for the mode of
healing (ie, nonsubmerged vs sub-
merged) as well as for the adjunc-
tive use of systemic antibiotics.
• Periimplantitis recurrence requir-
ing retreatment or leading to
implant loss was reported.
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